| Objective To analyze the effects of hormone replacement therapy (HRT) combined with alendronate sodium on patients with perimenopausal osteoporosis. Methods The study subjects were 82 cases of perimenopausal osteoporosis patients admitted to our hospital, the year of case collection was January 2022-December 2023, the grouping method was randomized throw method, and the grouping groups were the observation group (HRT + alendronate treatment) and the control group (alendronate treatment), with 41 cases in each group. Serum hormone levels [estradiol (E2), follicle-stimulating hormone (FSH)], bone metabolism levels [bone-specific alkaline phosphatase (BAP), anti-tartaric acid phosphatase-5b (TRAP-5b), β-collagen specific sequence (β-CTX), osteocalcin (BGP)], bone mineral density indexes (lumbar vertebrae L2-L4, femoral necks on both sides), and safety of treatment were compared between the two groups.Translated with DeepL.com (free version). Results After 6 courses of treatment, compared with the control group, the FSH level and the levels of BAP, TRAP-5b, β-CTX, and BGP were lower in the observation group, and the levels of E2 and the BMD values of lumbar vertebrae L2-L4, the left femoral neck, and the right femoral neck were higher (P<0.05); and the incidence rates of side effects of the medications were compared between the 2 groups (7.32% vs. 12.20%, 2=0.138, P=0.709>0.05). Conclusion For patients with perimenopausal osteoporosis, HRT combined with alendronate sodium can not only effectively regulate the levels of E2 and FSH, but also actively improve the level of bone metabolism and increase bone mineral density to a certain extent, without serious adverse reactions. |